MAM
CBAY

Meeder Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Meeder Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,770
Closed -$77K – 2308
2020
Q3 		$77K Buy
+10,770
New +$57.6K 0.01% 856
2020
Q2 		– Sell
-3,519
Closed -$5K – 2572
2020
Q1 		$5K Buy
3,519
+2,150
+157% +$3.61K ﹤0.01% 1823
2019
Q4 		$3K Buy
1,369
+965
+239% +$3.63K ﹤0.01% 1960
2019
Q3 		$2K Sell
404
-1,586
-80% -$9.6K ﹤0.01% 2006
2019
Q2 		$14K Sell
1,990
-849
-30% -$9.61K ﹤0.01% 1359
2019
Q1 		$38K Buy
2,839
+2,142
+307% +$22.8K ﹤0.01% 937
2018
Q4 		$5K Buy
+697
New +$6.63K ﹤0.01% 1430

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return